These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

556 related articles for article (PubMed ID: 22612696)

  • 1. Drug-loaded nanocarriers: passive targeting and crossing of biological barriers.
    Rabanel JM; Aoun V; Elkin I; Mokhtar M; Hildgen P
    Curr Med Chem; 2012; 19(19):3070-102. PubMed ID: 22612696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanocarriers for oral drug delivery.
    Zhang L; Wang S; Zhang M; Sun J
    J Drug Target; 2013 Jul; 21(6):515-27. PubMed ID: 23621127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and disposition of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) nanoparticles.
    Song X; Zhao X; Zhou Y; Li S; Ma Q
    Curr Drug Metab; 2010 Dec; 11(10):859-69. PubMed ID: 21208172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent progress of drug nanoformulations targeting to brain.
    Khan AR; Yang X; Fu M; Zhai G
    J Control Release; 2018 Dec; 291():37-64. PubMed ID: 30308256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery.
    Roger E; Lagarce F; Garcion E; Benoit JP
    Nanomedicine (Lond); 2010 Feb; 5(2):287-306. PubMed ID: 20148639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral bioavailability: issues and solutions via nanoformulations.
    Pathak K; Raghuvanshi S
    Clin Pharmacokinet; 2015 Apr; 54(4):325-57. PubMed ID: 25666353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nano carriers for drug transport across the blood-brain barrier.
    Li X; Tsibouklis J; Weng T; Zhang B; Yin G; Feng G; Cui Y; Savina IN; Mikhalovska LI; Sandeman SR; Howel CA; Mikhalovsky SV
    J Drug Target; 2017 Jan; 25(1):17-28. PubMed ID: 27126681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of injectable drug nanocrystals.
    Fuhrmann K; Gauthier MA; Leroux JC
    Mol Pharm; 2014 Jun; 11(6):1762-71. PubMed ID: 24766270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid-based nanocarriers as an alternative for oral delivery of poorly water- soluble drugs: peroral and mucosal routes.
    Silva AC; Santos D; Ferreira D; Lopes CM
    Curr Med Chem; 2012; 19(26):4495-510. PubMed ID: 22834821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PLGA nanoparticles prepared by nano-emulsion templating using low-energy methods as efficient nanocarriers for drug delivery across the blood-brain barrier.
    Fornaguera C; Dols-Perez A; Calderó G; García-Celma MJ; Camarasa J; Solans C
    J Control Release; 2015 Aug; 211():134-43. PubMed ID: 26057857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanocarriers for cancer-targeted drug delivery.
    Kumari P; Ghosh B; Biswas S
    J Drug Target; 2016; 24(3):179-91. PubMed ID: 26061298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral delivery of proteins by biodegradable nanoparticles.
    Bakhru SH; Furtado S; Morello AP; Mathiowitz E
    Adv Drug Deliv Rev; 2013 Jun; 65(6):811-21. PubMed ID: 23608641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Denatured globular protein and bile salt-coated nanoparticles for poorly water-soluble drugs: Penetration across the intestinal epithelial barrier into the circulation system and enhanced oral bioavailability.
    He W; Yang K; Fan L; Lv Y; Jin Z; Zhu S; Qin C; Wang Y; Yin L
    Int J Pharm; 2015 Nov; 495(1):9-18. PubMed ID: 26325310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanocarriers: a general strategy for enhancement of oral bioavailability of poorly absorbed or pre-systemically metabolized drugs.
    Cai Z; Wang Y; Zhu LJ; Liu ZQ
    Curr Drug Metab; 2010 Feb; 11(2):197-207. PubMed ID: 20384585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights on Oral Drug Delivery of Lipid Nanocarriers: a Win-Win Solution for Augmenting Bioavailability of Antiretroviral Drugs.
    Nabi B; Rehman S; Baboota S; Ali J
    AAPS PharmSciTech; 2019 Jan; 20(2):60. PubMed ID: 30623263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcellular drug targeting, pharmacokinetics and bioavailability.
    Leucuta SE
    J Drug Target; 2014 Feb; 22(2):95-115. PubMed ID: 24188545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymeric particulate technologies for oral drug delivery and targeting: a pathophysiological perspective.
    Hunter AC; Elsom J; Wibroe PP; Moghimi SM
    Nanomedicine; 2012 Sep; 8 Suppl 1():S5-20. PubMed ID: 22846372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Carrier Geometry in Overcoming Biological Barriers to Drug Delivery.
    Jordan C; Shuvaev VV; Bailey M; Muzykantov VR; Dziubla TD
    Curr Pharm Des; 2016; 22(9):1259-73. PubMed ID: 26675218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro/in-vivo characterization of trans-resveratrol-loaded nanoparticulate drug delivery system for oral administration.
    Singh G; Pai RS
    J Pharm Pharmacol; 2014 Aug; 66(8):1062-76. PubMed ID: 24779896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solid lipid nanoparticles: an oral bioavailability enhancer vehicle.
    Harde H; Das M; Jain S
    Expert Opin Drug Deliv; 2011 Nov; 8(11):1407-24. PubMed ID: 21831007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.